RS is an independent measure for BCSS and recurrence prognoses relative to OS in early-stage breast cancer. It carries more prognostic information for breast cancer-specific outcomes.
Keyphrases
- phase iii
- clinical trial
- early stage
- double blind
- open label
- phase ii
- free survival
- placebo controlled
- genome wide
- study protocol
- copy number
- cross sectional
- type diabetes
- randomized controlled trial
- gene expression
- health information
- sentinel lymph node
- adipose tissue
- dna methylation
- metabolic syndrome
- genome wide identification
- social media
- weight loss